SAN DIEGO--(BUSINESS WIRE)--A four-year prospective study showed that bioTheranostics’ CancerTYPE ID® molecular test successfully predicted the site of origin in patients diagnosed with cancer of unknown primary (CUP), helping to direct site-specific treatment and improve survival. The first-ever prospective evaluation of molecular tumor profiling in the clinical management of CUP was published online Monday in the Journal of Clinical Oncology.
